SCHEDULE 13G/A: venBio Global Strategic Fund III Reports Reduced Passive Stake in Artiva Biotherapeutics to 4.9%

venBio Global Strategic Fund III, L.P. and its affiliated entities have reported a passive beneficial ownership of 4.9% in Artiva Biotherapeutics, Inc., holding 1,198,975 shares of common stock as of March 31, 2025.

Summary

• The filing is an Amendment No. 2 to Schedule 13G, reporting beneficial ownership in Artiva Biotherapeutics, Inc. (Issuer).
• The reporting persons include venBio Global Strategic Fund III, L.P., VENBIO GLOBAL STRATEGIC GP III, L.P., VENBIO GLOBAL STRATEGIC GP III, LTD, Robert Adelman, and Corey Goodman.
• As of March 31, 2025, the reporting persons collectively beneficially own 1,198,975 shares of Artiva Biotherapeutics, Inc. Common Stock.
• This ownership represents 4.9% of the Issuer's class of securities.
• The percentage is based on 24,363,119 shares outstanding as of March 31, 2025, as reported in the Issuer's definitive proxy statement on Schedule 14A filed on April 29, 2025.
• The reporting persons hold shared voting power and shared dispositive power over the 1,198,975 shares.
• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the implied reduction in a significant investor's stake, which can be interpreted as a decrease in conviction or a reallocation of capital, despite the filing being routine.

Positives

• The venBio entities maintain a substantial, passive investment of 1,198,975 shares in Artiva Biotherapeutics, Inc., indicating continued, albeit reduced, confidence in the company.

Negatives

• The reporting persons' beneficial ownership in Artiva Biotherapeutics, Inc. has decreased to 4.9% of the common stock, which is below the 5% threshold that typically triggers initial Schedule 13G filings, suggesting a reduction in their stake from a prior filing.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding Artiva Biotherapeutics, Inc.'s future performance or strategic direction. It is solely a disclosure of beneficial ownership.

Management Comments

• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Artiva Biotherapeutics, Inc., nor in connection with any transaction having that purpose or effect, other than activities solely related to a nomination under Rule 14a-11.

Industry Context

This filing reflects a change in the ownership stake of a significant institutional investor in a biotechnology company. While specific industry trends are not discussed, changes in major investor positions can reflect broader sentiment or strategic shifts within the life sciences investment landscape.

Stakeholder Impact

• Shareholders: The disclosure of a reduced stake by a significant institutional investor may influence investor sentiment and potentially the stock price, as it could signal a change in investment thesis or capital allocation by venBio.

Key Dates

Keywords

Artiva Biotherapeutics, venBio, Schedule 13G, beneficial ownership, passive investment, common stock, institutional investor, biotechnology